US EditionFDA reinstates ousted top vaccine regulator Vinay Prasad
- Dr. Vinay Prasad stepped down from his position overseeing the FDA’s vaccine and gene therapy office in late July 2025, but was reinstated to the role within two weeks.
- Prasad's departure followed backlash over his handling of Sarepta Therapeutics' gene therapy linked to patient deaths and conservative criticism led by activist Laura Loomer.
- FDA Commissioner Marty Makary publicly campaigned for Prasad's return, describing him as a needed scientific leader while Loomer called the rehiring 'egregious' and pledged ongoing critiques.
- HHS spokesperson Andrew Nixon stated that Prasad is returning to head the FDA office responsible for biologics evaluation and research, following a request from the agency, and may take on additional responsibilities.
- Prasad's rehiring highlights continued agency tensions amid political pressures and debate over drug safety, approval standards, and departmental personnel under the Trump administration.
Insights by Ground AI
Does this summary seem wrong?
111 Articles
111 Articles
Vinay Prasad Returns to FDA Role Amid Political Pressure
Dr. Vinay Prasad has been reinstated as director of the FDA’s Center for Biologics Evaluation and Research just over a week after stepping down. His brief departure followed mounting political pressure, but agency leaders have now brought him back, underscoring deep tensions within the FDA today. Dr. Prasad resigned at the end of July after facing backlash from conservative figures—including activist Laura Loomer—and castigation focused on his p…
Coverage Details
Total News Sources111
Leaning Left14Leaning Right8Center62Last UpdatedBias Distribution74% Center
Bias Distribution
- 74% of the sources are Center
74% Center
L 17%
C 74%
Factuality
To view factuality data please Upgrade to Premium
